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Abstract
Background: The literature is scarce regarding the prevalence and clinical impact of IgG subclass deficiency in
COPD. We investigated the prevalence of IgG subclass deficiencies and their association with exacerbations and
hospitalizations using subjects from two COPD cohorts.
Methods: We measured IgG subclass levels using immunonephelometry in serum samples from participants enrolled
in two previous COPD trials: Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO; n = 976) and
Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE; n = 653). All samples were
collected from clinically stable participants upon entry into both studies. IgG subclass deficiency was diagnosed when
IgG subclass levels were below their respective lower limit of normal: IgG1 < 2.8 g/L; IgG2 < 1.15 g/L; IgG3 < 0.24 g/L;
and IgG4 < 0.052 g/L. To investigate the impact of IgG subclass levels on time to first exacerbation or hospitalization,
we log-transformed IgG levels and performed Cox regression models, with adjustments for confounders.
Results: One or more IgG subclass deficiencies were found in 173 (17.7%) and 133 (20.4%) participants in MACRO and
STATCOPE, respectively. Lower IgG1 or IgG2 levels resulted in increased risk of exacerbations with adjusted hazard ratios (HR)
of 1.30 (95% CI, 1.10–1.54, p< 0.01) and 1.19 (95% CI, 1.05–1.35, p< 0.01), respectively in the MACRO study, with STATCOPE
yielding similar results. Reduced IgG1 or IgG2 levels were also associated with increased risk of hospitalizations: the adjusted
HR for IgG1 and IgG2 was 1.52 (95% CI: 1.15–2.02, p< 0.01) and 1.33 (95% CI, 1.08–1.64, p< 0.01), respectively for the MACRO
study; in STATCOPE, only IgG2 was an independent predictor of hospitalization. In our multivariate Cox models, IgG3 and
IgG4 levels did not result in significant associations for both outcomes in either MACRO or STATCOPE cohorts.
Conclusions: Approximately 1 in 5 COPD patients had one or more IgG subclass deficiencies. Reduced IgG subclass levels
were independent risk factors for both COPD exacerbations (IgG1 and IgG2) and hospitalizations (IgG2) in two COPD cohorts.
Trial registration: This study used serum samples from participants of the MACRO (NCT00325897) and STATCOPE
(NCT01061671) trials.
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Background
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality worldwide,
projected to become the third leading cause of death in
2020 [1]. The course of COPD is punctuated by episodes of
acute exacerbations, which result in worse quality of life,
accelerated disease progression, and increased risk of mor-
tality [1, 2]. Hospitalizations due to severe exacerbations
are associated with poor survival, with a 5-year mortality
rate of 55% based on a previous study [3]. Respiratory tract
infections are major triggers of COPD exacerbations [1, 4].
There is increasing evidence that immunoglobulins (Ig)
play a crucial role in preventing infections, particularly
sinopulmonary infections which likely relate to the con-
tinuous exposure of the anatomy involved to a vast range
of pathogens [5–9]. Immunoglobulin G (IgG) is the pre-
dominant Ig class, corresponding to 75–80% of total Ig
levels in blood, and consisting of four subclasses (IgG1,
IgG2, IgG3, and IgG4) [10, 11]. The primary mechanisms
by which IgG inactivates or eliminates pathogens involve
activation of the complement system and opsonization of
pathogens [12]. These processes result in target cell lysis
and enhanced phagocytosis, respectively [10, 13].
Recently, we demonstrated that hypogammaglobuline-
mia (defined as total IgG levels < 7.0 g/L) was present in
approximately 1 out of 4 patients with moderate to se-
vere COPD [14]. More importantly, those patients with
reduced IgG levels demonstrated 50% to 100% higher
risk for both exacerbations and hospitalizations. The re-
lationship between various subclasses of IgG and risk of
exacerbations, however, remains unknown, as only a few
articles with a number of limitations have described the
frequency of IgG subclass deficiencies in COPD[15–17]
and no prior studies have evaluated their impact on hos-
pitalizations. Considering that COPD is a heterogeneous
disease with several clinical phenotypes [18], we ana-
lyzed samples from patients who were at increased risk
for exacerbations, and a second independent COPD co-
hort was also used to replicate our findings.
Methods
Study design
This is a retrospective study which used samples from partic-
ipants of two COPD cohorts: Macrolide Azithromycin for
Prevention of Exacerbations of COPD (MACRO – First co-
hort; ClinicalTrials.gov number: NCT00325897) [19] and
Simvastatin for the Prevention of Exacerbations in
Moderate-to-Severe COPD (STATCOPE – Replication co-
hort; ClinicalTrials.gov number: NCT01061671) [20]. Briefly,
the MACRO trial tested azithromycin (250 mg daily), a
macrolide antibiotic with immunomodulatory and antibac-
terial effects, whereas the STATCOPE trial investigated sim-
vastatin (40 mg daily), compared to placebo for the
prevention of COPD exacerbations. Both trials were double-
blinded and placebo-controlled intervention studies. All par-
ticipants had a diagnosis of COPD, aged 40 years or older,
were current or former smokers (≥ 10 pack-year smoking
history), and had a forced expiratory volume in 1 s (FEV1) <
80% of predicted values after bronchodilator use.
Additionally, all subjects had to meet at least one of the
following inclusion criteria: use of supplemental oxygen, pre-
vious treatment with systemic glucocorticoids or antibiotic
agents for respiratory problems, or a history of an emergency
department visit or hospitalization for COPD exacerbation.
Exacerbation and hospitalization data
In both cohorts, the number and severity of exacerbations
that occurred during follow-up were captured. The follow-
ing scale was used to grade the severity of exacerbations: 1)
mild – treatment conducted at home, with or without con-
tacting a health care provider; 2) moderate – treatment re-
quiring a visit to the emergency department; 3) severe –
treatment requiring hospitalization; and 4) very severe – in
which patients needed intensive care unit (ICU) admission.
COPD-related hospitalizations were identified by capturing
all events graded as severe and very severe exacerbations.
IgG measurements
Baseline blood samples were collected from clinically
stable participants upon entry into both studies. A total of
978 and 654 samples from the MACRO and STATCOPE
cohorts, respectively, were available. Two samples from
the MACRO trial (azithromycin arm) and one sample
from the STATCOPE trial (placebo arm) were of insuffi-
cient quantity to allow measurements of all IgG subclasses
and were thus not included in the analysis. In total, IgG
levels were measured in 1629 samples, 976 from partici-
pants of MACRO (468 in the azithromycin arm; 508 in
the placebo arm) and 653 from participants of STAT-
COPE (322 in the simvastatin arm; 331 in the placebo
arm). Serum IgG subclass levels were measured using
Binding Site IgG subclass (IgG1–4) reagents (Birmingham,
UK) by immunonephelometry on a Siemens BNII nephel-
ometer (BNII; Erlangen, Germany). All samples were
processed in the clinical laboratory at St. Paul’s Hospital,
Vancouver, British Columbia, Canada. The following nor-
mal ranges for IgG subclasses in adults were used: IgG1,
2.80–8.00 g/L; IgG2, 1.15–5.70 g/L; IgG3, 0.24–1.25 g/L;
IgG4, 0.052–1.25 g/L [21]. These ranges were obtained
from a healthy population and include mean levels ±2
standard deviations [22]. IgG subclass deficiency was diag-
nosed when IgG levels were below their respective lower
limit of normal for each subclass: IgG1 < 2.80 g/L, IgG2 <
1.15 g/L, IgG3 < 0.24 g/L, and IgG4 < 0.052 g/L.
Statistical analysis
IgG subclass levels were not normally distributed, and thus
are presented as median and interquartile range. Categorical
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variables are shown as number and percentages. We used
the Mann-Whitney U test and the Pearson′s Chi-square test
to compare the IgG subclass levels and the frequency of IgG
subclass deficiencies between the two cohorts, respectively.
The Mann-Whitney U test was also applied to analyze the
IgG subclass levels according to the exacerbation status
(participants with zero or one exacerbation vs. participants
with two or more exacerbations) and the occurrence of hos-
pitalizations during follow-up. Additionally, we compared
the rates of COPD exacerbations in person-years (expressed
as the number of acute exacerbations divided by the duration
of follow-up in years) between participants with IgG subclass
levels below and above the lower limit of normal (LLN)
using the Mann-Whitney U test.
To investigate the effect of IgG levels on time to first
COPD exacerbation or hospitalization, we applied Cox
proportional-hazards regression models to obtain a hazard
ratio (HR) and its 95% confidence intervals (CI) associated
with these outcomes for each IgG subclass. In our Cox
models, we adjusted for covariates that were considered
biologically relevant to the outcomes of interest (exacerba-
tions and hospitalizations) or that presented with a p < 0.2
at the univariate analysis. The following variables were in-
cluded in our multivariate models: IgG subclass levels (log-
transformed), study drug (azithromycin in the derivation
cohort, or simvastatin in the validation cohort), age, gender,
ethnicity, smoking status, FEV1 (% of predicted value),
long-term oxygen therapy, inhaled corticosteroid therapy at
baseline, and history of systemic steroids in the year prior
to enrollment. To investigate any possible effect of steroids
(as described above) on IgG subclass levels, we also in-
cluded an interaction term in our multivariate models. For
IgG subclasses that demonstrated significant associations in
our time to event analyses, we also obtained the adjusted
predicted probabilities of COPD exacerbations or hospitali-
zations (using logistic regression models) and calculated the
Pearson’s correlation coefficient between these probabilities
and IgG-levels (log-transformed). SPSS version 22.0 for
Windows (IBM Corp., Armonk, NY, USA) was used for
data analysis. The level of statistical significance was set at
p < 0.05 for all tests.
Results
Characteristics of participants and prevalence of IgG deficiency
The details of participant characteristics at baseline are
presented in Table 1. In MACRO, the participants were
older (65.5 ± 8.6 vs. 62.8 ± 8.4 years, p < 0.001), were
more likely to be Caucasians (82.6% vs. 77.9%, p = 0.02)
and had slightly lower FEV1 (39.8 ± 15.7% vs. 41.5 ±
17.8%, p = 0.049), and a higher rate of long-term domi-
ciliary oxygen use (60.1% vs. 48.7%, p < 0.001) compared
with participants enrolled in STATCOPE. Conversely,
the prevalence of current smokers was higher in STAT-
COPE (28.8% vs. 21.2%, p < 0.001).
Total IgG and IgG subclass levels were similar between
both cohorts (Table 2). Overall, 306 (18.8%) participants in
the merged cohort (n= 1629) presented with at least one IgG
subclass deficiency (173 (17.7%) and 133 (20.4%) in MACRO
and STATCOPE, respectively)(Table 2). IgG3 deficiency was
the most frequent, whereas IgG1 deficiency was the least
common. We also identified cases showing two or more IgG
subclasses deficiencies simultaneously. The majority of
participants identified with an IgG subclass deficiency were
also diagnosed with hypogammaglobulinemia (defined as
total IgG < 7.0 g/L), especially participants presenting with
IgG1 (72/74, n= 97.3%) or IgG2 (69/93, 74.2%) deficiencies.
No differences regarding the frequency of IgG subclass defi-
ciencies between both MACRO and STATCOPE cohorts
were observed (Additional file 1: Table S1). The median and
interquartile range for each IgG subclass according to the
presence or absence of the related IgG subclass deficiency
are shown in Additional file 2: Tables S2 (First and Replica-
tion cohorts) and Additional file 3: Table S3 (merged cohort).
IgG subclass levels according to exacerbation status and
hospitalizations
In both cohorts, we detected significantly lower IgG1 and
IgG2 levels among participants who developed two or more
exacerbations during follow-up versus those who did not
have any exacerbations or developed only one exacerbation
(Additional file 4: Figure S1). Similar results were also ob-
served in both cohorts according to hospitalization status,
with participants who required hospitalizations during
follow-up presenting with lower IgG1 and IgG2 subclass
levels (Additional file 5: Figure S2).
Given the low frequency of IgG subclass deficiency (<
10%) for all IgG subclasses in both cohorts, we merged
both cohorts (n = 1629) and compared the rates of COPD
exacerbations per person-year between participants
according to the presence or not of IgG1–4 deficiencies.
We observed significantly higher rates of exacerbations per
person-year among participants with IgG1 deficiency (2.9 ±
5.46 vs. 1.48 ± 1.86, p < 0.001) and IgG2 deficiency (2.10 ±
1.99 vs. 1.51 ± 2.18, p = 0.001) compared to their counter-
parts with normal IgG1 and IgG2 levels (Fig. 1). Addition-
ally, the frequency of IgG1 and IgG2 deficiency was also
significantly higher among recurrent exacerbators com-
pared to participants who remained stable or presented
with only one exacerbation during the follow-up: IgG1–43/
644 (6.7%) vs. 31/985 (3.1%), p = 0.001; IgG2–47/644 (7.3%)
vs. 46/985 (4.7%), p = 0.025.
Impact of IgG subclass levels on time to first COPD
exacerbation and hospitalization
The adjusted HRs for having a COPD exacerbation in-
creased significantly with progressively lower IgG1 and
IgG2 levels in MACRO (HR: 1.30, 95% CI: 1.10–1.54, p =
0.002; HR: 1.19, 95% CI: 1.05–1.35, p = 0.006, respectively)
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Table 1 Baseline characteristics of participants in the MACRO and STATCOPE cohorts
Variable MACRO (n = 976) STATCOPE (n = 653) P*
Age, years 65.5 ± 8.6 62.8 ± 8.4 < 0.001
Gender (Male: Female) – no. (%) 584 (59.8):392 (40.2) 381 (58.3):272(41.7) 0.55
Ethnicity (Caucasian) – no. (%) 806 (82.6) 509 (77.9) 0.02
BMI, kg/m2 27.7 ± 6.2 27.1 ± 6.8 0.062
Current Smokers – no. (%) 207 (21.2) 188 (28.8) < 0.001
FVC, % predicted 70.2 ± 18.1 71.1 ± 19.1 0.29
FEV1, % predicted 39.8 ± 15.7 41.5 ± 17.8 0.049
Long-term oxygen therapy – no. (%) 587 (60.1) 318 (48.7) < 0.001
Systemic steroid use in previous year – no. (%) 822 (84.2) 550 (84.2) 0.99
Inhaled steroid use – no. (%) 764 (78.3) 484 (74.1) 0.06
IgG1 (g/L) 5.09 (2.45) 5.26 (2.70) 0.18
IgG2 (g/L) 2.57 (1.72) 2.61 (1.64) 0.82
IgG3 (g/L) 0.62 (0.49) 0.63 (0.51) 0.96
IgG4 (g/L) 0.21 (0.28) 0.22 (0.32) 0.99
Total IgG (g/L) 8.68 (3.72) 8.84 (4.00) 0.70
Values expressed as means ± SD. IgG levels expressed as median (interquartile range). *Student’s t-test, Mann–Whitney U-test (for comparisons of IgG levels), or
Chi-square test, as appropriate. Definition of abbreviations: BMI body mass index, FVC forced vital capacity, FEV1 forced expiratory volume in one second, IgG
immunoglobulin G
Table 2 Frequency of IgG subclass deficiency according to the presence or absence of associated hypogammaglobulinemia in the
merged cohort (MACRO and STATCOPE cohorts combined)
IgG abnormality Merged Cohort (n = 1629)
IgG1 deficiency – no. (%) 74 (4.5%)
With hypogammaglobulinemia – no. (%) 72 (4.4%)
No hypogammaglobulinemia – no. (%) 2 (0.1%)
IgG2 deficiency – no. (%) 93 (5.7%)
With hypogammaglobulinemia – no. (%) 69 (4.2%)
No hypogammaglobulinemia – no. (%) 24 (1.5%)
IgG3 deficiency – no. (%) 124 (7.6%)
With hypogammaglobulinemia – no. (%) 72 (4.4%)
No hypogammaglobulinemia – no. (%) 52 (3.2%)
IgG4 deficiency – no. (%) 114 (7.0%)
With hypogammaglobulinemia – no. (%) 73 (4.5%)
No hypogammaglobulinemia – no. (%) 41 (2.5%)
One or more IgG subclass deficiency – no. (%) 306 (18.8%)
With hypogammaglobulinemia – no. (%) 197 (12.1%)
No hypogammaglobulinemia – no. (%) 109 (6.7%)
Two IgG subclass deficiencies combined – no. (%) 47 (2.9%)
With hypogammaglobulinemia – no. (%) 37 (2.3%)
No hypogammaglobulinemia – no. (%) 10 (0.6%)
Three IgG subclass deficiencies combined – no. (%)a 20 (1.2%)
All IgG subclass deficiencies combined – no. (%)a 4 (0.2%)
The normal range for IgG levels in adults used in this analysis were: IgG1, 2.8–8.0 g/L; IgG2, 1.15–5.70 g/L; IgG3, 0.24–1.25 g/L; IgG4, 0.052–1.250 g/L; total IgG,
7.0–16.0 g/L. aAll participants were diagnosed with hypogammaglobulinemia (total IgG < 7.0 g/L).
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(Table 3). Since the IgG subclass levels in our models were
expressed using a negative base-2 logarithmic scale, for
every one-unit increase on this log scale, the IgG subclass
levels decreased by 50% (negative log22 = − 1). Thus, in
MACRO, a 50% reduction of IgG1 levels was associated
with a 30% higher adjusted HR for COPD exacerbations.
A similar reduction in IgG2 levels resulted in a 19% higher
adjusted HR for this outcome. These findings were repli-
cated in STATCOPE, as the adjusted HRs related to COPD
exacerbations were 1.25 (95% CI: 1.02–1.54, p = 0.035) and
1.17 (95% CI: 1.01–1.36, p = 0.046) for IgG1 and IgG2, re-
spectively. IgG1 and IgG2 levels were also associated with
hospitalizations in MACRO: the adjusted HR for every 50%
reduction of IgG1 level was 1.52 (95% CI: 1.15–2.02, p =
0.004) and for IgG2 was 1.33 (95% CI: 1.08–1.64, p = 0.007)
(Table 4). In STATCOPE, only decreased IgG2 levels re-
sulted in a higher risk of hospitalizations (adjusted HR =
1.43, 95% CI: 1.12–1.83, p = 0.004). We also detected an in-
verse relationship between IgG levels (log-transformed) and
the adjusted predicted risk of COPD exacerbations (Fig. 2)
and hospitalizations (Fig. 3) in MACRO and STATCOPE
cohorts (p < 0.05 for both outcomes).
In our multivariate Cox models, IgG3 and IgG4 levels did
not result in significant associations for both outcomes in
either MACRO or STATCOPE cohorts. For these two IgG
subclasses, we also calculated the HRs using both cohorts
combined (n = 1629) and obtained similar HRs compared
Fig. 1 Comparison of rates of COPD exacerbations in person-years between participants with IgG subclass deficiency and normal IgG subclass
levels in the merged dataset (MACRO and STATCOPE cohorts combined, n = 1629). Error bars represent 95% confidence interval
Table 3 Unadjusted and adjusted hazard ratios for COPD
exacerbations according to IgG subclass levels in the MACRO
and STATCOPE cohorts
MACRO – Time to first Exacerbation
IgGa Univariate analysis Multivariate analysisb
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
IgG1 1.43 (1.23–1.67) < 0.001 1.30 (1.10–1.54) 0.002
IgG2 1.29 (1.15–1.45) < 0.001 1.19 (1.05–1.35) 0.006
IgG3 0.99 (0.88–1.11) 0.84 0.95 (0.85–1.07) 0.39
IgG4 1.09 (1.02–1.17) 0.009 1.05 (0.98–1.13) 0.17
STATCOPE – Time to first Exacerbation
IgGa Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
IgG1 1.45 (1.20–1.75) < 0.001 1.25 (1.02–1.54) 0.035
IgG2 1.32 (1.15–1.52) < 0.001 1.17 (1.01–1.36) 0.046
IgG3 1.10 (0.98–1.25) 0.11 0.99 (0.87–1.13) 0.90
IgG4 1.01 (0.94–1.08) 0.76 0.96 (0.89–1.04) 0.33
aIgG subclass levels expressed using a negative-log transformation (base 2), with
one-unit increase on this log scale being equivalent to a 50% decrease of IgG
subclass levels. bAdjusted hazard ratios for IgG levels were calculated using a Cox
Proportional Hazards model with adjustments for the following covariates: study
drug (azithromycin vs. placebo in MACRO - First cohort; simvastatin vs. placebo in
STATCOPE - Replication cohort), age, gender, ethnicity (Caucasian vs.
Non-Caucasian), FEV1 (% of predicted values), smoking status (current vs. former
smokers), oxygen dependence, inhaled corticosteroid use, and treatment with
systemic steroids in previous year. Legend: 95% CI = 95% Confidence Interval
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to analyzing the cohorts separately: IgG3 (exacerbations:
HR = 0.97, 95% CI: 0.89–1.05, p = 0.53; hospitalizations:
HR = 0.97, 95% CI: 0.84–1.12, p = 0.70); IgG4 (exacerba-
tions: HR = 1.01, 95% CI: 0.96–1.06, p = 0.71; hospitaliza-
tions: 1.02, 95% CI: 0.94–1.12, p = 0.59).
We observed a trend for lower IgG1 subclass levels
among participants who were treated with systemic ste-
roids in the year prior to enrollment (MACRO - out-
come: time to first exacerbation, p = 0.057; STATCOPE -
outcome: time to first hospitalization, p = 0.07) (Add-
itional file 6: Table S4). No statistically significant inter-
actions were observed between IgG subclass levels and
inhaled steroid therapy in both cohorts for either exacer-
bations or hospitalizations.
Discussion
In this study, we found that IgG subclass deficiency was
common in COPD, affecting approximately 1 in 5 patients
who were at increased risk for COPD exacerbations. In
addition, progressively lower IgG1 and IgG2 levels were
associated with increased risk of exacerbations and hospi-
talizations in two different COPD cohorts. Moreover, the
protective effect of IgG1 and IgG2 was even more pro-
nounced on hospitalizations compared to exacerbations in
both analyzed cohorts, emphasizing the potential role of
IgG subclass levels in modulating the frequency and sever-
ity of COPD exacerbations.
Table 4 Unadjusted and adjusted hazard ratios related to
hospitalizations according to IgG subclass levels in the MACRO
and STATCOPE cohorts
MACRO – Time to first Hospitalization
IgGa Univariate analysis Multivariate analysisb
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
IgG1 1.51 (1.16–1.99) 0.003 1.52 (1.15–2.02) 0.004
IgG2 1.37 (1.12–1.67) 0.002 1.33 (1.08–1.64) 0.007
IgG3 1.03 (0.85–1.24) 0.79 1.01 (0.84–1.44) 0.90
IgG4 1.01 (0.89–1.12) 0.99 1.00 (0.88–1.12) 0.94
STATCOPE – Time to first Hospitalization
IgGa Univariate analysis Multivariate analysisb
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
IgG1 1.33 (0.98–1.80) 0.07 1.27 (0.91–1.76) 0.16
IgG2 1.39 (1.11–1.74) 0.004 1.43 (1.12–1.83) 0.004
IgG3 0.97 (0.79–1.19) 0.75 0.90 (0.73–1.12) 0.36
IgG4 1.08 (0.95–1.22) 0.22 1.06 (0.93–1.20) 0.39
aIgG subclass levels expressed using a negative-log transformation (base 2), with one-
unit increase on this log scale being equivalent to a 50% decrease of IgG subclass
levels. bAdjusted hazard ratios for IgG levels were calculated using a Cox Proportional
Hazards model with adjustments for the following covariates: study drug (azithromycin
vs. placebo in MACRO - First cohort; simvastatin vs. placebo in STATCOPE - Replication
cohort), age, gender, ethnicity (Caucasian vs. Non-Caucasian), FEV1 (% of predicted
values), smoking status (current vs. former smokers), oxygen dependence, inhaled
corticosteroid use, and treatment with systemic steroids in previous year. Legend: 95%
CI = 95% Confidence Interval
Fig. 2 Correlation of IgG1 (upper panel) and IgG2 (lower panel) levels (log-transformed, base2) and the predicted risk of COPD exacerbations. For
each participant, the predicted risks were calculated using logistic regression models with adjustments for the following covariates: study drug
(azithromycin vs. placebo in MACRO - First cohort; simvastatin vs. placebo in STATCOPE - Replication cohort), age, gender, ethnicity (Caucasian vs.
non-Caucasian), FEV1 (% of predicted values), smoking status (current vs. former smokers), oxygen dependence, inhaled corticosteroid use, and
treatment with systemic steroids in previous year
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Several prior reports have described the prevalence of
IgG subclass deficiency in COPD patients [15–17].
O’Keeffe et al. observed an IgG subclass deficiency in 15
of 58 COPD patients (25.9%) [15]. Qvarfordt et al. mea-
sured IgG subclass levels in 33 smokers with chronic
bronchitis and recurrent exacerbations, identifying an
IgG subclass deficiency in 6 patients (18%) [16]. We ob-
tained similar results, as at least one IgG subclass defi-
ciency was detected in 17.7% and 20.4% of participants
with COPD in MACRO and STATCOPE cohorts, re-
spectively. Concerning the distribution of IgG subclass
deficiency, we identified IgG3 as the most frequent
(6.7% in MACRO and 9.0% of cases in STATCOPE),
which has also been reported by other studies [16, 23].
Our findings suggest that the frequency of IgG abnor-
malities may be even higher among COPD patients who
present with multiple exacerbations, as we detected a
higher frequency of IgG1 and IgG2 deficiency among re-
current exacerbators. This is supported by a previous
article, in which IgA, IgG, and IgM were measured in 42
COPD patients who had 2 or more moderate to severe
exacerbations per year [24]. The authors detected in 29
patients (69%) evidence of an antibody deficiency syn-
drome, with 8 patients receiving a diagnosis of common
variable immunodeficiency syndrome, whose diagnosis
requires reduced total IgG levels [25]. Similarly, we
observed significantly lower IgG1 and IgG2 levels among
COPD participants who developed exacerbations and re-
quired hospitalizations in both cohorts.
In our Cox proportional hazards regression models, re-
ductions in IgG1 and IgG2 levels in the First cohort were
associated with an increased risk of COPD exacerbations
and hospitalizations. These results remained statistically
significant after adjustments for differences in age, gender,
race, study drug, smoking status, oxygen dependence, FEV1
(% of predicted values), use of inhaled steroids and treat-
ment with systemic steroids in the year prior to enrollment.
Similar results were detected using a second independent
cohort (thus increasing the validity of our findings) [26],
with the exception that only IgG2 remained as an inde-
pendent predictor of hospitalizations. Additionally, we also
showed that participants with IgG1 and/or IgG2 deficiency
presented with higher rates of COPD exacerbations per
person-year during follow-up. To the best of our know-
ledge, this is the first report to demonstrate that lower IgG
subclass levels are independent risk factors for both COPD
exacerbations (IgG1 and IgG2) and hospitalizations (IgG2).
Our results are in line with some important concepts re-
lated to the biology of IgG subclasses. IgG1 and IgG2 are the
major components of serum total IgG levels, explaining why
patients with deficiencies in either one of these subclasses
(or both) are more likely to present with reduced total IgG
Fig. 3 Correlation of IgG1 (upper panel) and IgG2 (lower panel) levels (log-transformed, base2) and the predicted risk of hospitalizations. For each
participant, the predicted risks were calculated using logistic regression models with adjustments for the following covariates: study drug
(azithromycin vs. placebo in MACRO - First cohort; simvastatin vs. placebo in STATCOPE - Replication cohort), age, gender, ethnicity (Caucasian vs.
non-Caucasian), FEV1 (% of predicted values), smoking status (current vs. former smokers), oxygen dependence, inhaled corticosteroid use, and
treatment with systemic steroids in previous year
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levels (i.e., hypogammaglobulinemia) [10, 11, 25]. We ob-
served that 97.3% and 74.2% of patients diagnosed with IgG1
and IgG2 deficiencies (considering the merged cohort) also
met criteria for hypogammaglobulinemia, respectively. Thus,
patients with lower IgG1 and IgG2 levels, through a reduc-
tion in total IgG levels, may present with an increased risk of
COPD exacerbations and hospitalizations, as these outcomes
are mostly triggered by respiratory infections [4]. This is con-
sistent with a previous work of our group, in which COPD
patients with hypogammaglobulinemia showed a higher fre-
quency of COPD exacerbations and hospitalizations com-
pared to patients with normal total IgG levels [14].
Additionally, patients with IgG2 deficiency usually present
with impaired polysaccharide responses, leading to a higher
susceptibility to infections caused by encapsulated pathogens
(e.g., Streptococcus pneumoniae and Haemophilus influenzae
type B) [10, 12, 13], which are frequently implicated in bac-
terial COPD exacerbations [4].
It has been shown that not all patients with lower IgG sub-
classes present with recurrent infections, with some healthy
individuals also being diagnosed with one or more IgG sub-
classes deficiencies [11]. Conversely, there is a rationale for
evaluating patients with recurrent infections for possible IgG
subclass deficiency. Kim JH et al. observed that one-third of
patients with chronic airway diseases (asthma, COPD, or
asthma COPD overlap syndrome) who had received a previ-
ous diagnosis of IgG subclass deficiency (n= 59) presented
with a history of recurrent respiratory infections [23]. Add-
itionally, these patients showed a higher frequency of hospi-
talizations and a faster FEV1 decline during follow-up. Our
results indicate that IgG1 or IgG2 subclass deficiency may
contribute to a higher exacerbation risk, and thus we advo-
cate that measurement of IgG subclass levels be considered
in any COPD patient with a history of several exacerbations
or previous hospitalizations. Moreover, in this scenario, even
if a COPD patient shows normal total IgG levels, it is still
possible that an IgG1 or IgG2 subclass deficiency may be
present, potentially contributing to an increased propensity
to COPD exacerbations. In a previous article, Vendrell et al.
found that 11% of patients with bronchiectasis of unknown
etiology with normal total IgG levels (n= 107) still had an
antibody production deficiency, with 50% of those presenting
with IgG2 deficiency [27].
The management of IgG subclass deficiency includes
vaccinations, prophylactic antibiotics, treatment of allergy
and sinopulmonary disease (if present) and cautious use
of immunoglobulin G replacement therapy - IVIG (for pa-
tients who persist with recurrent infections despite these
interventions) [25]. In one previous study, administration
of IVIG reduced the risk of respiratory infections by over
50% in 92/132 adults with IgG subclass deficiency present-
ing with recurrent infections [28]. In another study, IVIG
significantly decreased the frequency of moderate to se-
vere exacerbations by nearly 90% in 14 COPD patients
(from an annual COPD exacerbation rate of 4.7 ± 3.1 to
0.6 ± 1.0 per patient)[29]. Interestingly, 64.3% of the par-
ticipants (9/14) had evidence of hypogammaglobulinemia.
Our study had several limitations. Firstly, we were only
able to measure IgG subclass levels at baseline, and thus we
cannot determine how IgG subclass levels fluctuate over the
course of COPD or with the implementation of various
COPD treatments. Secondly, we only measured IgG subclass
levels once, despite standard laboratory recommendations
that two measurements be performed at least 1 month apart
to confirm deficiency [11, 25]. Thirdly, we did not investigate
whether patients with IgG subclass deficiency had impaired
humoral immunity, usually evaluated by measuring antibody
levels after a pneumococcal vaccination [11, 13, 25]. Finally,
since this is a retrospective, observational study, we can only
describe an association between low serum IgG1 or IgG2
levels and COPD exacerbations. Although IgG subclass defi-
ciency may serve as a biomarker to identify subjects at in-
creased risk of exacerbation, our study was not designed to
determine if low serum IgG subclass levels are linked on a
causal pathway to COPD exacerbations. It is worth mention-
ing we analyzed samples from moderate-to-severe COPD
patients who were at increased risk of COPD exacerbations;
thus the effect of lower IgG levels on the outcomes of COPD
patients with mild disease or without a history of prior exac-
erbations was not evaluated by our study.
Conclusions
Our data support that IgG subclass deficiency is relatively
common among COPD patients and that decreased IgG1
and IgG2 levels result in an increased risk of adverse out-
comes in COPD. Future prospective studies are needed to
better elucidate the impact of these IgG subclass deficien-
cies on the management of high-risk COPD patients and
whether they represent a modifiable risk factor for COPD
exacerbations and hospitalizations through IVIG.
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